Of the 85 patients enrolled in the interventional R2CHOP cohort (HOVON-130 trial), 8 patients were ineligible for the present analysis (three because a MYC translocation could not be confirmed, and one because of transformed synchronous follicular lymphoma and four could not be identified in the NCR database). This evidence concerns the gene MYC and follicular lymphoma.